we report the results of a randomized double-blind , multicenter trial comparing sulfinpyrazone ( 200 mg four times a day ) and a placebo in the prevention of cardiac mortality among 1558 patients followed for an average of 16 months , beginning 25 to 35 days after a documented myocardial infarction .
C0018787
cardiac
C0027051
myocardial infarction